AI Screening for Lung Cancer

This trial tests a new AI tool called Sybil to determine if it predicts lung cancer risk more effectively than current methods. Researchers aim to discover whether using Sybil and expanding screening criteria can identify more individuals at risk for lung cancer. Participants will be divided into groups based on existing screening guidelines and will either receive a low-dose CT scan or be observed. The trial seeks individuals aged 50-80 with a history of significant smoking who are willing to watch a short educational video about the AI tool.

As an unphased trial, this study allows participants to contribute to innovative research that could enhance future lung cancer screening methods.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that the Sybil AI tool effectively predicts lung cancer risk. Studies indicate that Sybil can accurately forecast future lung cancer risk using just one low-dose CT scan, helping identify individuals who might need more careful monitoring.

Importantly, Sybil itself poses no direct safety concerns because it is not a drug or physical treatment. As a tool that analyzes images and data to make predictions, it carries a very low risk of side effects.

Researchers are excited about the AI screening for lung cancer because it leverages cutting-edge technology to potentially enhance early detection. Unlike traditional methods like low-dose CT scans, this approach involves Sybil AI, which generates a personalized lung cancer risk score. This innovative technique could improve screening accuracy by identifying at-risk individuals who might not meet standard screening criteria, like those outlined by the United States Preventative Service Task Force. By refining risk assessment, this AI screening method promises to make lung cancer detection more precise and accessible.

Research shows that Sybil, an artificial intelligence (AI) tool, can effectively predict the risk of lung cancer. Studies have found that Sybil accurately assesses a person's future lung cancer risk from just one low-dose CT scan. This AI model operates with little bias, making it a promising option for personalized screening. Sybil achieved a high accuracy score, with a 92% success rate for predicting lung cancer within 1 year and 75% within 6 years. In this trial, participants in Cohorts 1 and 2 will receive a low-dose CT scan and review their Sybil AI lung cancer risk score, while Cohort 3 will be observational with no Sybil score disclosure. These findings suggest that Sybil could be a valuable addition to lung cancer screening methods.¹²³⁶⁷